Asciminib after stem cell transplant for leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called asciminib given after a stem cell transplant to prevent the return of a type of leukemia. If you have Philadelphia chromosome-positive B-ALL or blast-phase CML, this may help keep you in remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have Philadelphia chromosome-positive B-ALL or blast-phase CML and have had a stem cell transplant
- You have received a tyrosine kinase inhibitor (TKI) during earlier treatment
- Your blood counts (neutrophils and platelets) are at certain minimum levels
- You do not have uncontrolled high blood pressure or heart rhythm problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug asciminib after a stem cell transplant or CAR T-cell therapy for adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) to help prevent the cancer from coming back.
This trial lets people who already have Philadelphia chromosome–positive (Ph+) leukemia and are benefiting from asciminib (or certain related medicines) continue treatment. It mainly tests whether ongoing care in a follow-on study is safe and workable for participants.
This trial tests a pill called asciminib given after a stem cell transplant or CAR T therapy to help prevent relapse in adults with Philadelphia chromosome-positive ALL. It is for people whose cancer is currently in remission.
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
This study tests how well asciminib works and how safe it is for people with a type of blood cancer called chronic myeloid leukemia (CML). It helps see if asciminib is a good option compared to other standard treatments.
This trial tests an oral medication called asciminib in children and teens with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It aims to see if the drug is safe and effective for patients who are newly diagnosed or whose current treatment has stopped working or caused side effects.
Hear when a new Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.